Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 38.70 |
---|---|
High | 40.70 |
Low | 38.70 |
Bid | 39.50 |
Offer | 40.60 |
Previous close | 39.90 |
Average volume | 306.67 |
---|---|
Shares outstanding | 6.47bn |
Free float | 342.99m |
P/E (TTM) | 29.77 |
Market cap | 284.01bn USD |
EPS (TTM) | 1.46 USD |
Annual div (ADY) | 1.25 EUR |
---|---|
Annual div yield (ADY) | 3.11% |
Div ex-date | Mar 14 2024 |
Div pay-date | May 03 2024 |
Data delayed at least 15 minutes, as of Mar 12 2025 16:20 BST.
More ▼
- Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity
- Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston
- FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
- Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies
- CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
- Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
- FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
- New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis
- FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
- Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
More ▼